Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis And Quark Partner On Phase II siRNA Drug For Kidney Damage Indications

This article was originally published in The Pink Sheet Daily

Executive Summary

Already partnered in RNA interference with Alnylam, Novartis pays $10 million for an option to Quark's QPI-1002.

You may also be interested in...



Deals Of The Week: Medco/United BioSource, Aspen/Sigma, Biogen/Knopp ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Deals Of The Week: Medco/United BioSource, Aspen/Sigma, Biogen/Knopp ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Launch Delays In U.S. Dampen Dr. Reddy's Q1 Earnings But Money Starts Flowing From GSK Deal; Analysts Confident On Future Outlook

MUMBAI - The first tangible benefits of the deal Dr. Reddy's Labs struck last year with GlaxoSmithKline for supply of over 100 branded formulations have become visible with the Indian company receiving $4 million from its British partner in return for moving dossiers and trademarks for nine currently marketed products in Brazil

Topics

UsernamePublicRestriction

Register

OM006051

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel